InflaRx N.V.
IFRX
Positions held
Your positionsIFRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $225.47M | Enterprise value | $67.79M | Trailing P/E | — | Forward P/E | -3.95 |
| PEG | — | Price / book | 1.37 | Beta | 2.61 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 3529.7% |
| Profit margin | 0.0% | ROE | -38.5% | ROA | -18.5% | Debt / equity | 0.01 |
| Current ratio | 8.22 | Free cash flow | -$4.31M | Analyst recommendation | none | Mean target | $7.67 |
| 52w high | $2.95 | 52w low | $0.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | -$0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | 37891.1% | -39769.2% | -32812.2% | — |
| Net income | -$10.6M | -$5.6M | -$10.6M | -$12.3M | -$14.4M | — |
| Gross margin | — | — | 14418.5% | 98.6% | -5985.4% | — |
| Gross profit | $0.0M | $0.0M | -$4.9M | $0.0M | -$2.4M | — |
| Operating income | -$7.0M | -$7.2M | -$12.9M | -$9.5M | -$12.9M | — |
- Gross margin 14418.5% (was 98.6% prior quarter).
- Operating margin expanded to 37891.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.2M | $0.1M | $0.0M |
| Op margin | -164525.5% | -31911.4% | -70685.6% | — |
| Net income | -$45.6M | -$46.1M | -$42.7M | -$29.5M |
| Gross margin | -24677.9% | -1900.8% | -743.7% | — |
| Gross profit | -$7.2M | -$3.2M | -$0.5M | $0.0M |
| Operating income | -$48.3M | -$52.9M | -$44.6M | -$32.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
2026-10-01 · InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
2026-09-21 · InflaRx to Host Virtual Capital Markets Day
2026-09-14 · Needham Initiates InflaRx at Buy With $8 Price Target
2026-08-20 · InflaRx Announces Participation in September Investor Conferences
2026-08-06 · InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
2026-08-04 · Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
2026-07-30 · InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Price (daily)
Full chart · RSI · MACD · patterns